Reuters logo
Lexicon Pharma's diabetes drug successful in mid-stage study
April 14, 2014 / 10:16 AM / 4 years ago

Lexicon Pharma's diabetes drug successful in mid-stage study

April 14 (Reuters) - Lexicon Pharmaceuticals Inc said its experimental drug to treat diabetes met the main goal of reducing the use of insulin at meal times in a mid-stage study on patients with type 1 diabetes.

The company’s shares rose about 19 percent to $1.89 in trading before the bell.

Lexicon said the drug, codenamed LX4211, reduced the total dose of insulin taken by patients at meal times by 32 percent, compared with a 6 percent reduction in patients given a placebo. (Reporting by Vrinda Manocha in Bangalore; Editing by Kirti Pandey)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below